Bridgeway Capital Management, LLC Glycomimetics Inc Transaction History

Bridgeway Capital Management, LLC

$4.76 Billion
Q1 2024

A detailed history of Bridgeway Capital Management, LLC transactions in Glycomimetics Inc stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 168,600 shares of GLYC stock, worth $55,638. This represents 0.01% of its overall portfolio holdings.

Number of Shares

168,600

Previous 197,200 14.5%

Holding current value

$55,638

Previous $465,000 8.6%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.55 - $3.49 $72,930 - $99,814	-28,600 Reduced 14.5%	168,600 $505,000
Q4 2023 Feb 14, 2024	BUY	$1.13 - $2.54 $28,249 - $63,500	25,000 Added 14.52%	197,200 $465,000
Q3 2023 Nov 14, 2023	BUY	$1.29 - $1.73 $46,827 - $62,799	36,300 Added 26.71%	172,200 $258,000
Q2 2023 Aug 14, 2023	BUY	$1.21 - $2.08 $30,855 - $53,040	25,500 Added 23.1%	135,900 $236,000
Q1 2023 May 15, 2023	BUY	$1.25 - $4.05 $37,500 - $121,500	30,000 Added 37.31%	110,400 $139,000

Q4 2022 Feb 14, 2023	SELL	$0.67 - $3.03 $50,250 - $227,249	-75,000 Reduced 48.26%	80,400 $243,000
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.14 $19,152 - $28,462	-13,300 Reduced 7.88%	155,400 $224,000
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $84,600 - $112,330	-47,000 Reduced 21.79%	168,700 $369,000
Q2 2021 Aug 16, 2021	BUY	$2.16 - $3.18 $97,200 - $143,100	45,000 Added 26.36%	215,700 $500,000
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $99,705 - $145,590	-34,500 Reduced 16.81%	170,700 $514,000
Q4 2020 Feb 16, 2021	SELL	$2.69 - $4.24 $10,491 - $16,536	-3,900 Reduced 1.87%	205,200 $772,000
Q3 2020 Nov 16, 2020	SELL	$3.07 - $5.0 $555,363 - $904,500	-180,900 Reduced 46.38%	209,100 $642,000
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $277,688 - $506,848	134,800 Added 52.82%	390,000 $1.47 Million
Q1 2020 May 15, 2020	BUY	$1.83 - $5.41 $289,506 - $855,862	158,200 Added 163.09%	255,200 $582,000
Q4 2019 Feb 14, 2020	SELL	$4.03 - $6.5 $275,652 - $444,600	-68,400 Reduced 41.35%	97,000 $513,000
Q3 2019 Nov 14, 2019	BUY	$2.8 - $12.85 $463,119 - $2.13 Million	165,400 New	165,400 $713,000
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $292,600 - $383,800	-20,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$16.06 - $25.35 $269,229 - $424,967	-16,764 Reduced 45.6%	20,000 $325,000
Q4 2017 Feb 14, 2018	SELL	$10.51 - $17.22 $315,300 - $516,599	-30,000 Reduced 44.93%	36,764 $617,000
Q3 2017 Nov 14, 2017	BUY	$10.14 - $14.85 $676,986 - $991,445	66,764	66,764 $934,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

36.8M

Call Options Held

969K

Put Options Held

636K

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $17.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.

Account

Bridgeway Capital Management, LLC Glycomimetics Inc Transaction History